Dallas-based Lantern Pharma has announced promising early results from its Phase 2 HARMONIC clinical trial for never smokers with advanced non-small cell lung cancer. The AI-driven drug developer reported an 86% clinical benefit rate among participants, along with a 43% objective response rate, signaling strong therapeutic activity.
